{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:49:19Z","timestamp":1791319759660,"version":"4.3.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Background The clinical features and therapeutic strategies for gastric cancer with positive peritoneal washing cytology but without visible gross peritoneal metastasis have not been defined. The aim of this study was to evaluate the effect and clinical prognostic value of postoperative chemotherapy in gastric cancer patients with positive peritoneal washing cytology without gross peritoneal metastasis who underwent radical D2 gastrectomy in terms of disease-free survival (DFS) and overall survival (OS). Materials and Methods Intraoperative peritoneal washing cytology was performed in 285 patients who underwent radical D2 gastrectomy between April 2004 and May 2016. Of them, 88 patients with positive cytology but without gross peritoneal metastasis were included in the study. In total, 64 patients received postoperative chemotherapy, whereas 24 patients underwent surgery only. Results Most gastric cancer patients with positive cytology without gross peritoneal metastasis demonstrated pT4 and\/or pN3 disease. Postoperative chemotherapy improved DFS and OS compared to surgery only in gastric cancer patients with positive cytology without gross peritoneal metastasis (median DFS 11.63 vs. 6.98 months, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; median OS 25.50 vs. 12.11 months, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). In multivariate analyses of gastric cancer patients with positive cytology without gross peritoneal metastasis, no chemotherapy was the strongest clinical factor for poorer DFS (hazard ratio [HR] 3.76, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) or OS (HR 4.37, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Conclusion Postoperative chemotherapy improves the survival outcome compared to surgery alone in gastric cancer patients with positive peritoneal washing cytology but without visible gross peritoneal metastasis who underwent radical D2 gastrectomy.<\/jats:p>","DOI":"10.1038\/s41598-020-66637-y","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T10:03:06Z","timestamp":1591956186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Observational Study of Peritoneal Washing Cytology-Positive Gastric Cancer without Gross Peritoneal Metastasis in Patients who Underwent Radical D2 Gastrectomy"],"prefix":"10.1038","volume":"10","author":[{"given":"Hyun-Jeong","family":"Shim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Jong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Hyuk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo-Kyun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eu-Chang","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Hee","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ik-Joo","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Jin","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Eul","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"66637_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","volume":"3","author":"C Fitzmaurice","year":"2017","unstructured":"Fitzmaurice, C. et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA oncology 3, 524\u2013548, https:\/\/doi.org\/10.1001\/jamaoncol.2016.5688 (2017).","journal-title":"JAMA oncology"},{"key":"66637_CR2","doi-asserted-by":"publisher","first-page":"292","DOI":"10.4143\/crt.2017.118","volume":"49","author":"KW Jung","year":"2017","unstructured":"Jung, K. W. et al. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014. Cancer research and treatment: official journal of Korean Cancer Association 49, 292\u2013305, https:\/\/doi.org\/10.4143\/crt.2017.118 (2017).","journal-title":"Cancer research and treatment: official journal of Korean Cancer Association"},{"key":"66637_CR3","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto, S. et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. The New England journal of medicine 357, 1810\u20131820, https:\/\/doi.org\/10.1056\/NEJMoa072252 (2007).","journal-title":"The New England journal of medicine"},{"key":"66637_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/s0140-6736(11)61873-4","volume":"379","author":"YJ Bang","year":"2012","unstructured":"Bang, Y. J. et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet (London, England) 379, 315\u2013321, https:\/\/doi.org\/10.1016\/s0140-6736(11)61873-4 (2012).","journal-title":"Lancet (London, England)"},{"key":"66637_CR5","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1200\/jco.2011.36.5908","volume":"29","author":"M Sasako","year":"2011","unstructured":"Sasako, M. et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 29, 4387\u20134393, https:\/\/doi.org\/10.1200\/jco.2011.36.5908 (2011).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"66637_CR6","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/s1470-2045(14)70473-5","volume":"15","author":"SH Noh","year":"2014","unstructured":"Noh, S. H. et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. The Lancet. Oncology 15, 1389\u20131396, https:\/\/doi.org\/10.1016\/s1470-2045(14)70473-5 (2014).","journal-title":"The Lancet. Oncology"},{"key":"66637_CR7","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/01.sla.0000143245.28656.15","volume":"240","author":"M D\u2019Angelica","year":"2004","unstructured":"D\u2019Angelica, M. et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Annals of surgery 240, 808\u2013816 (2004).","journal-title":"Annals of surgery"},{"key":"66637_CR8","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1159\/000083600","volume":"22","author":"C Brigand","year":"2004","unstructured":"Brigand, C., Arvieux, C., Gilly, F. N. & Glehen, O. Treatment of peritoneal carcinomatosis in gastric cancers. Digestive diseases (Basel, Switzerland) 22, 366\u2013373, https:\/\/doi.org\/10.1159\/000083600 (2004).","journal-title":"Digestive diseases (Basel, Switzerland)"},{"key":"66637_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejso.2013.10.019","volume":"40","author":"F Coccolini","year":"2014","unstructured":"Coccolini, F. et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 40, 12\u201326, https:\/\/doi.org\/10.1016\/j.ejso.2013.10.019 (2014).","journal-title":"European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology"},{"key":"66637_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/jso.23632","volume":"110","author":"JP De Andrade","year":"2014","unstructured":"De Andrade, J. P. & Mezhir, J. J. The critical role of peritoneal cytology in the staging of gastric cancer: an evidence-based review. Journal of surgical oncology 110, 291\u2013297, https:\/\/doi.org\/10.1002\/jso.23632 (2014).","journal-title":"Journal of surgical oncology"},{"key":"66637_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1245\/aso.2005.03.065","volume":"12","author":"D Bentrem","year":"2005","unstructured":"Bentrem, D., Wilton, A., Mazumdar, M., Brennan, M. & Coit, D. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Annals of surgical oncology 12, 347\u2013353, https:\/\/doi.org\/10.1245\/aso.2005.03.065 (2005).","journal-title":"Annals of surgical oncology"},{"key":"66637_CR12","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1007\/s00432-019-02963-7","volume":"145","author":"JE Hwang","year":"2019","unstructured":"Hwang, J. E. et al. Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer. Journal of cancer research and clinical oncology 145, 2157\u20132166, https:\/\/doi.org\/10.1007\/s00432-019-02963-7 (2019).","journal-title":"Journal of cancer research and clinical oncology"},{"key":"66637_CR13","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.ejca.2011.12.017","volume":"48","author":"GM Kim","year":"2012","unstructured":"Kim, G. M. et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. European journal of cancer (Oxford, England: 1990) 48, 518\u2013526, https:\/\/doi.org\/10.1016\/j.ejca.2011.12.017 (2012).","journal-title":"European journal of cancer (Oxford, England: 1990)"},{"key":"66637_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/s1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi, W. et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. The Lancet. Oncology 9, 215\u2013221, https:\/\/doi.org\/10.1016\/s1470-2045(08)70035-4 (2008).","journal-title":"The Lancet. Oncology"},{"key":"66637_CR15","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1200\/jco.2007.13.9378","volume":"26","author":"SE Al-Batran","year":"2008","unstructured":"Al-Batran, S. E. et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 26, 1435\u20131442, https:\/\/doi.org\/10.1200\/jco.2007.13.9378 (2008).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"66637_CR16","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10120-011-0117-2","volume":"15","author":"DH Koo","year":"2012","unstructured":"Koo, D. H. et al. Three-week combination chemotherapy with S-1 and cisplatin as first-line treatment in patients with advanced gastric cancer: a retrospective study with 159 patients. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 15, 305\u2013312, https:\/\/doi.org\/10.1007\/s10120-011-0117-2 (2012).","journal-title":"Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association"},{"key":"66637_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10120-016-0662-9","volume":"20","author":"D Kobayashi","year":"2017","unstructured":"Kobayashi, D. & Kodera, Y. Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20, 111\u2013121, https:\/\/doi.org\/10.1007\/s10120-016-0662-9 (2017).","journal-title":"Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association"},{"key":"66637_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/s1470-2045(15)00553-7","volume":"17","author":"K Fujitani","year":"2016","unstructured":"Fujitani, K. et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. The Lancet. Oncology 17, 309\u2013318, https:\/\/doi.org\/10.1016\/s1470-2045(15)00553-7 (2016).","journal-title":"The Lancet. Oncology"},{"key":"66637_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s10120-017-0749-y","volume":"21","author":"S Jamel","year":"2018","unstructured":"Jamel, S. et al. Prognostic significance of peritoneal lavage cytology in staging gastric cancer: systematic review and meta-analysis. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 21, 10\u201318, https:\/\/doi.org\/10.1007\/s10120-017-0749-y (2018).","journal-title":"Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association"},{"key":"66637_CR20","first-page":"4859","volume":"35","author":"M Yamamoto","year":"2015","unstructured":"Yamamoto, M. et al. Comparison of Neoadjuvant Chemotherapy to Surgery Followed by Adjuvant Chemotherapy in Japanese Patients with Peritoneal Lavage Cytology Positive for Gastric Carcinoma. Anticancer research 35, 4859\u20134863 (2015).","journal-title":"Anticancer research"},{"key":"66637_CR21","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1245\/s10434-019-07697-x","volume":"27","author":"T Yamaguchi","year":"2020","unstructured":"Yamaguchi, T. et al. Efficacy of postoperative chemotherapy after resection that leaves no macroscopically visible disease of gastric cancer with positive peritoneal lavage cytology (CY1) or localized peritoneum metastasis (P1a): A multicenter retrospective study. Annals of surgical oncology 27, 284\u2013292, https:\/\/doi.org\/10.1245\/s10434-019-07697-x (2020).","journal-title":"Annals of surgical oncology"},{"key":"66637_CR22","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/s0140-6736(10)61121-x","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (London, England) 376, 687\u2013697, https:\/\/doi.org\/10.1016\/s0140-6736(10)61121-x (2010).","journal-title":"Lancet (London, England)"},{"key":"66637_CR23","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdy540","volume":"30","author":"N Boku","year":"2019","unstructured":"Boku, N. et al. Safety and efficacy of nivolumab in combination with S-1\/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Annals of oncology: official journal of the European Society for Medical Oncology 30, 250\u2013258, https:\/\/doi.org\/10.1093\/annonc\/mdy540 (2019).","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology"},{"key":"66637_CR24","doi-asserted-by":"publisher","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","volume":"27","author":"EC Smyth","year":"2016","unstructured":"Smyth, E. C. et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology 27, v38\u2013v49, https:\/\/doi.org\/10.1093\/annonc\/mdw350 (2016).","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66637-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66637-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66637-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T12:30:59Z","timestamp":1670329859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66637-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["66637"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-66637-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,12]]},"assertion":[{"value":"30 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9549"}}